Jolene Quinones
Family · Chicago, ILNPI 1750624581
Payments from drug & device makers
Across 279 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$877
- Lilly USA, LLC$590
- Boehringer Ingelheim$574
- Pfizer$562
- AstraZeneca$460
- GSK$335
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,01899%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $877 |
| Lilly USA, LLC | 32 | $590 |
| Boehringer Ingelheim | 29 | $574 |
| Pfizer | 27 | $562 |
| AstraZeneca | 31 | $460 |
| GSK | 23 | $335 |
| Amgen | 19 | $307 |
| Novartis | 17 | $304 |
| AbbVie | 15 | $297 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $142 |
| Merck | 7 | $123 |
| Astellas Pharma US Inc | 6 | $100 |
| E.r. Squibb & Sons, L.L.C. | 4 | $79 |
| Exact Sciences | 3 | $71 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Intuity Medical Inc | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 1 | $27 |
| Dexcom, Inc. | 1 | $24 |
| Vistapharm, Inc. | 2 | $23 |
| Phadia US Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $3 |
How this compares
$5,055 in reported general payments places this provider in the 90th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 23 | $29,135 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $25,725 |
| EliquisApixaban | 16 | $12,076 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $7,617 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,138 |
| Atorvastatin Calcium | 169 | $1,418 |
| Levothyroxine Sodium | 80 | $1,191 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $735 |
| Metoprolol Succinate | 39 | $628 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 37 | $472 |
| Amlodipine Besylate | 62 | $431 |
| Metformin Hcl | 39 | $362 |
| Alprazolam | 50 | $354 |
| Pantoprazole Sodium | 26 | $342 |
| Lisinopril | 48 | $331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $574 | $29,13523 claims |
| GSKTrelegy Ellipta | $335 | $25,72523 claims |
| PfizerEliquis | $562 | $12,07616 claims |
| AstraZenecaBreztri Aerosphere | $460 | $7,13811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,941 family providers in Illinois.
Other family in Chicago
- Ruth CarricoChicago$582K
- Jamie BroganChicago$282K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Brittony CroasdellChicago$192K
- Stephanie Bradley-MillerChicago$156K
- Elizabeth LegorretaChicago$150K
- Staci GorsonChicago$61K
- Allison MoserChicago$60K
- Darcie McDonaughChicago$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.